Hunan Fangsheng Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 603998.SS

Hunan Fangsheng Pharmaceutical Co., Ltd. Current Liabilities for the year ending December 31, 2023: USD 175.79 M

Hunan Fangsheng Pharmaceutical Co., Ltd. Current Liabilities is USD 175.79 M for the year ending December 31, 2023, a 21.36% change year over year. Current liabilities are obligations that are expected to be settled within one year, including accounts payable, short-term debt, and other current liabilities.

Hunan Fangsheng Pharmaceutical Co., Ltd. Current Liabilities for the year ending December 31, 2022 was USD 144.85 M, a -26.69% change year over year.
Hunan Fangsheng Pharmaceutical Co., Ltd. Current Liabilities for the year ending December 31, 2021 was USD 197.58 M, a 47.14% change year over year.
Hunan Fangsheng Pharmaceutical Co., Ltd. Current Liabilities for the year ending December 31, 2020 was USD 134.29 M, a 35.70% change year over year.
Hunan Fangsheng Pharmaceutical Co., Ltd. Current Liabilities for the year ending December 31, 2019 was USD 98.96 M, a 44.87% change year over year.

Key data

Date	Current Liabilities	Total Non-Current Liabilities	Shareholders' Equity	Long-Term Debt

Shanghai Stock Exchange: 603998.SS

Hunan Fangsheng Pharmaceutical Co., Ltd.

CEO	Ms. Xiaoli Zhou
IPO Date	Dec. 5, 2014
Location	China
Headquarters	No. 299, Jiayun Road
Employees	1,686
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Drugstores & Retail Pharmacies

Description

Hunan Fangsheng Pharmaceutical Co., Ltd. researches and develops, produces, and sells pharmaceutical products in China. It offers medicines in the form of tablets, capsules, and granules for cardiovascular and cerebrovascular, orthopedic, pediatric, gynecological, traumatology, and anti-infectives. The company was founded in 2002 and is based in Changsha, China.

Key trends

Past 5 years